Literature DB >> 21703204

Role of cardiac myofilament proteins titin and collagen in the pathogenesis of diastolic dysfunction in cirrhotic rats.

Tamara K Glenn1, Hooman Honar, Hongqun Liu, Henk E D J ter Keurs, Samuel S Lee.   

Abstract

BACKGROUND & AIMS: Significance of diastolic dysfunction in cirrhotic cardiomyopathy has been brought to the forefront with several reports of unexpected heart failure following liver transplantation and transjugular intrahepatic portosystemic stent-shunt, but the etiology remains unclear. The present study investigated the role of passive tension regulators - titin and collagen - in the pathogenesis of this condition.
METHODS: Cirrhosis was induced by bile duct ligation (BDL) in rats, while controls underwent bile duct inspection with no ligation. Four weeks after operation, cardiac mRNA and protein levels of titin, collagen, and protein kinase A (PKA) were determined. Diastolic function was examined in isolated right ventricular cardiomyocytes, while passive tension was examined in right ventricular trabeculae muscles.
RESULTS: In BDL animals, diastolic return velocity was significantly decreased, relaxation time increased and passive tension increased. However, no significant difference in mRNA and protein levels of titin was observed. PKA mRNA and protein levels were significantly decreased in BDL animals. Collagen levels were also significantly altered in the BDL group.
CONCLUSIONS: Therefore, diastolic dysfunction exists in cirrhosis with alterations in titin modulation, PKA levels, and collagen configuration contributing to the pathogenesis of this condition.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703204     DOI: 10.1016/j.jhep.2011.02.030

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  14 in total

1.  Assessment of diastolic function in the management of patients with cirrhosis.

Authors:  Søren Møller
Journal:  Hepatol Int       Date:  2014-07-27       Impact factor: 6.047

Review 2.  Left ventricular function assessment in cirrhosis: Current methods and future directions.

Authors:  Francisco Sampaio; Joana Pimenta
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Recent advances in cirrhotic cardiomyopathy.

Authors:  Dimitrios S Karagiannakis; George Papatheodoridis; Jiannis Vlachogiannakos
Journal:  Dig Dis Sci       Date:  2014-11-18       Impact factor: 3.199

4.  Left atrial function is impaired in cirrhosis: a speckle tracking echocardiographic study.

Authors:  Francisco Sampaio; Joana Pimenta; Nuno Bettencourt; Ricardo Fontes-Carvalho; Ana Paula Silva; João Valente; Paulo Bettencourt; José Fraga; Vasco Gama
Journal:  Hepatol Int       Date:  2013-08-27       Impact factor: 6.047

5.  Cardiac remodelling identified by cardiovascular magnetic resonance in patients with hepatitis C infection and liver disease.

Authors:  Phillip J Ngu; Michelle Butler; Alan Pham; Stuart K Roberts; Andrew J Taylor
Journal:  Int J Cardiovasc Imaging       Date:  2015-12-15       Impact factor: 2.357

6.  Cirrhotic cardiomyopathy: review of pathophysiology and treatment.

Authors:  Maneerat Chayanupatkul; Suthat Liangpunsakul
Journal:  Hepatol Int       Date:  2014-07       Impact factor: 6.047

Review 7.  Diastolic dysfunction in cirrhosis.

Authors:  Søren Møller; Signe Wiese; Hanne Halgreen; Jens D Hove
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

Review 8.  Cirrhotic cardiomyopathy.

Authors:  Luis Ruiz-del-Árbol; Regina Serradilla
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

9.  Diagnosis and Management of Cirrhotic Cardiomyopathy.

Authors:  Harpreet Kaur; Madhumita Premkumar
Journal:  J Clin Exp Hepatol       Date:  2021-08-21

Review 10.  A Review of Cardiovascular Toxicity of Microcystins.

Authors:  Linghui Cao; Isaac Yaw Massey; Hai Feng; Fei Yang
Journal:  Toxins (Basel)       Date:  2019-08-30       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.